CPIX
CUMBERLAND PHARMACEUTICALS INCMarquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $1.43 | $5.12 | +258% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $1.39 | $5.12 | +268% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $1.39 | $5.12 | +268% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q2 2025 | Q1 2026 | → $3.85 | -27% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at CUMBERLAND PHARMACEUTICALS INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Mar 20, 2026 — the most recent Form 4 on file — not from today.
- Form 40001087294-26-000040Mar 20, 2026
- Form 40001632384-26-000002Mar 20, 2026
- Form 40001087294-26-000039Mar 20, 2026
- Form 40001087294-26-000037Mar 20, 2026
- Form 40001087294-26-000036Mar 20, 2026
- Form 40001087294-26-000035Mar 20, 2026
- Form 40001087294-26-000034Mar 20, 2026
- Form 40001087294-26-000033Mar 20, 2026
- Form 40001572342-26-000002Mar 20, 2026
- Form 40001087294-26-000032Mar 20, 2026
- Form 40001628280-26-019514Mar 18, 2026
- Form 40001087294-26-000008Jan 6, 2026
- Form 40001087294-26-000006Jan 6, 2026
- Form 40001087294-26-000004Jan 6, 2026
- Form 40001087294-26-000002Jan 6, 2026
Fundamentals
XBRL · CUMBERLAND PHARMACEUTICALS INCAnnual figures sourced directly from CUMBERLAND PHARMACEUTICALS INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for CUMBERLAND PHARMACEUTICALS INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 8, 2026
- 8-KMaterial eventMay 5, 2026
- 8-KMaterial eventApr 24, 2026
- 8-KFORM 8-KApr 23, 2026
- DEF 14AProxy statementMar 9, 2026
- 10-KAnnual reportMar 9, 2026
- 8-KMaterial eventMar 3, 2026
- 8-KMaterial eventFeb 4, 2026
- 8-KMaterial eventNov 24, 2025
- 10-QQuarterly reportNov 7, 2025
- 8-KMaterial eventNov 4, 2025
- 8-KMaterial eventOct 21, 2025
- 10-QQuarterly reportAug 8, 2025
- 8-KMaterial eventAug 5, 2025
- 10-QQuarterly reportMay 9, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2025 | open | $5.24 | $5.12 | -2% |
| Millennium Management | Q2 2025 | Q1 2026 | $5.24 | $3.85 | -27% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $1.39 | $1.20 | -14% |
| Two Sigma Investments | Q3 2024 | open | $1.39 | $5.12 | +268% |
| Renaissance Technologies | Q3 2024 | open | $1.43 | $5.12 | +258% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.